UNSPSC 51432109: Guanadrel sulfate

This classification denotes an antihypertensive agent with the molecular formula 2C10H19N3O2.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier MT147RMO91, chemically known as (1,4-dioxaspiro(4.5)dec-2-ylmethyl)guanidine but more generally known as guanadrel sulfate, which bears US NIH Compound Identifier 38521. European Medicines Agency schedules Guanadrel sulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02424MIG.

Most nations, for tariff and trade purposes, schedule guanadrel sulfate under HS 29329970 and SITC 51569. As of Q4 2014, GUANADREL SULFATE remains US FDA's Preferred Term for this commodity. Guanadrel sulfate bears US NLM identifiers UMLS ID C0304525 and NCI Concept Code C65828. SMILES: C1CCC2(CC1)OCC(O2)CNC(=N)N.C1CCC2(CC1)OCC(O2)CNC(=N)N.OS(=O)(=O)O.

UNSPSC 51432109 Guanadrel sulfate, a Commodity code, encompasses pharmaceutical supply contracts for state and local government agencies, fire rescue departments, and health systems procuring emergency medications and prescription pharmaceuticals. State and local purchasing offices solicit under this code to supply advanced life support medications, generic multi-source pharmaceuticals, and over-the-counter products for emergency medical services, hospital systems, and Medicaid pharmacy benefit programs. Issuing bodies include municipal fire departments (such as Tampa Fire Rescue), state health and human services commissions (such as the Texas HHS Commission), and multistate cooperative purchasing alliances (such as MMCAP, administered by the Minnesota Department of Administration). These procurements typically require vendors to meet FDA compliance, Good Manufacturing Practices (cGMP) certification, Drug Supply Chain Security Act (DSCSA) compliance, and Safety Data Sheet documentation under OSHA standards. Delivery timelines are tight—often within ten calendar days of order receipt—and products must maintain expiration dates of nine months or more from acceptance, with vendors responsible for pickup and replacement of expired stock.

Recent activity spans multiple states and procurement models. The City of Tampa issued an IFB (Bid No. 26-P-00188) in April 2026 for four specific advanced life support medications (Labetalol, Epinephrine, Adenosine, and Diltiazem) with an estimated contract value of $40,000, a one-year initial term with two optional renewals, and a Small Local Business Enterprise sheltered-market designation offering a 5 percent bid discount. The Minnesota Multistate Cooperative Purchasing Alliance issued an RFP in January 2026 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products to be distributed across state and local government facilities in Minnesota and Oregon, with vendor pricing weighted 75 percent and contract effectiveness beginning July 1, 2026. The Texas HHS Commission posted an RFI in April 2026 to explore direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels, signaling future formal solicitations. The code shows active engagement from municipal procurement offices, state health agencies, and cooperative purchasing vehicles, with opportunities concentrated in fire-rescue emergency medications and state pharmacy benefit programs.